Lead, a known neurotoxicant, has previously received attention in Parkinson’s disease (PD) research, but epidemiologic studies have been limited in sample size and findings are equivocal. We generated two methylation-based biomarkers for cumulative tibia and patella bone-measured lead exposure in 1528 PD patients and 1169 controls. PD status was associated with increased levels of the DNAm biomarker for tibia-lead levels. We estimated a meta-OR for PD of 1.89 per unit DNAm tibia-lead increase (95% CI 1.59, 2.24; p = 8.1E−13). The current study supports the notion that chronic and long-term lead exposure tracked via DNAm may contribute to PD pathogenesis.
CITATION STYLE
Paul, K. C., Horvath, S., Del Rosario, I., Bronstein, J. M., & Ritz, B. (2021). DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease. Clinical Epigenetics, 13(1). https://doi.org/10.1186/s13148-021-01051-3
Mendeley helps you to discover research relevant for your work.